Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
2 raisons identifiées
Disponibilité géographique
3 lieux d'exercice — choisissez celui qui vous arrange
Délais de RDV courts dans la région
150.8 rhumatos / 100 000 hab. — département bien doté
✨ Génération du profil synthétique IA en cours…
CENTRE D'IMAGERIE MEDICALE DU QUAI DE JUILLET
39 41 39 QUAI DE JUILLET, 14000 CAEN
CLINIQUE DE LA MISERICORDE
15 R DES FOSSES SAINT JULIEN BP 100, 14000 CAEN
GIE IMAGERIE MISERICORDE
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
CLINIQUE DE LA MISERICORDE 15 R DES FOSSES SAINT JULIEN, 14000 CAEN
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
La Revue de medecine interne · 1993
Lasers in surgery and medicine · 2025
ABSTRACTObjectivesLimited‐cutaneous systemic sclerosis (lcSSc), formerly known as CREST syndrome (calcinosis, Raynaud phenomenon, esophageal dysmotility, scleroderma, and telangiectasias) is an auto‐immune connective tissue disease characterized by cutaneous fibrosis and systemic fibrovascular dysfunction. The cutaneous fibrosis of lcSSc is commonly limited to acral sites, with perioral involvement seen in 70%–85% of cases. Patients often seek treatment of lcSSc‐associated microstomia for functional and cosmetic purposes. Treatments for the cutaneous sclerosis in systemic sclerosis (SSc) include topical agents, systemic immunosuppressants, phototherapy, and other less commonly used systemic medications. More recently fractional ablative laser therapy with the carbon dioxide (CO2) laser has been utilized in scarring disorders of the skin with notable improvement in cutaneous fibrosis. Here we report a case of a 54‐year‐old female with lcSSc‐associated microstomia treated with fractional ablative CO2 laser. The goal of treatment was to improve the objective size of the oral aperture and improve subjective symptoms, including oral mobility, speech, and eating.Materials and MethodsThe Lumenis Ultra Pulse CO2 laser was used to fractionally ablate the target peri‐oral skin. Pulses were performed up to but not crossing the vermillion border circumferentially around the mouth. Measurements in centimeters were taken pretreatment as well as 2 and 5 months posttreatment. Appropriate infectious prophylaxis was provided to the patient.ResultsNotable increases were observed at 2 and 5 months follow‐ups in horizontal width (+14.3%), vertical height (+12.1%), and cross‐sectional areas (+28.1%) of the oral aperture following a single treatment with CO2 laser. Subjective improvements in oral mobility, speech, and daily activities such as eating were noted by the patient.ConclusionAblative fractional CO2 laser is an effective and efficient method for the treatment of microstomia secondary to systemic sclerosis with minimal adverse effects. Utilizing this therapeutic treatment can significantly impact the quality of life in patients with lcSSc‐associated microstomia.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Lasers in surgery and medicine · 2025 · Case Reports
Fisher C, Woodside SS, Martin YE, Mak EL, et al.
La Revue de medecine interne · 1993 · Case Reports
Dupuy O, Benefice S, Martin Y, Michel P, et al.